文献速递腹部技术与安全MR

结直肠癌肝转移:ADC作为肿瘤行为与治疗反应的影像生物标志物

Colorectal liver metastases: ADC as an imaging biomarker of tumor behavior and therapeutic response.
PubMed 文献 · Eur J Radiol · 2021-02-22

化疗后ADC值及ADC变化值与TRG显著相关(均p<0.0001),化疗前ADC值在不同TRG间分布不同(p=0.0027)但非线性;RECIST1.1评估与TRG亦显著相关(p=0.0009)。化疗后ADC及ΔADC可能作为评估术前化疗后肿瘤治疗反应的可靠生物标志物。

要点

  • 化疗后ADC值及ΔADC与病理TRG显著相关,均p<0.0001,可用于评估治疗反应。
  • 化疗前ADC值在不同TRG间分布不同(p=0.0027),但分布并非线性。
  • RECIST1.1评估与TRG显著相关(p=0.0009),支持形态学评估的补充价值。

关键影像表现/征象

  • 化疗后58个病灶中8个消失;TRG1、TRG2、TRG3、TRG4、TRG5分别见于6、12、12、13、7个病灶。
  • 化疗前ADC值在不同TRG评分间分布不同(p=0.0027),但分布并非线性。
  • 化疗后ADC值与ΔADC值在不同TRG间均存在显著差异(均p<0.0001)。

诊断标准与关键数值

  • 以病理TRG为参考,化疗后ADC与ΔADC在不同TRG间均显著不同(均p<0.0001)。
  • 化疗前ADC在不同TRG间分布不同(p=0.0027),但非线性。
  • RECIST1.1评估与病灶TRG显著相关(p=0.0009)。

临床应用与阅片要点

  • 对结直肠癌肝转移术前化疗患者,可测量化疗前后病灶ADC值并计算ΔADC,辅助评估病理治疗反应。
  • 化疗前ADC值在不同TRG间分布呈非线性的差异,解读时不宜按单一阈值线性推断反应程度。
  • RECIST1.1形态学评估与TRG显著相关,可与ADC指标结合用于报告。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To correlate the ADC values of colorectal liver metastases, evaluated before (preADC) and after (postADC) neoadjuvant chemotherapy (ChT), as well as their difference (ΔADC), with the histological tumor regression grade (TRG) and to determine whether the preADC value can be predictive of the lesion ChT response.

METHOD: Twenty-four patients with colorectal liver metastases, who had undergone 3 T-MRI before and after ChT and were subsequently treated by parenchymal-spearing surgery, were retrospectively included. Diffusion-weighted MRI (DW-MRI) was performed using a spin-echo echo-planar sequence with multiple b values, obtaining an ADC map. Fitted ADC values were calculated for each lesion before and after ChT. The maximum diameter of each lesion in both examinations was recorded. Diameter variations and RECIST1.1 criteria were assessed. All MRI findings were histopathologically correlated to TRG of resected liver metastases. Statistical analysis was performed on a per-lesion basis.

RESULTS: A total of 58 colorectal liver metastases were analysed; after ChT, 8 out of 58 lesions disappeared. TRG1, TRG2, TRG3, TRG4 and TRG5 were observed in 6, 12, 12, 13 and 7 lesions, respectively. The preADC values showed a different distribution according to the TRG scores (p = 0.0027), even though the distribution was not linear. The postADC and ΔADC values were significant different based on the TRG system (both p < 0.0001). A significant correlation between the lesion TRG and the evaluation according to RECIST1.1 criteria was observed by a per-lesion analysis (p = 0.0009).

CONCLUSIONS: PostADC and ΔADC could be proposed as reliable biomarkers to assess tumor treatment response after preoperative ChT in patients with colorectal liver metastases.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Boraschi P, Donati F, Cervelli R, et al. Colorectal liver metastases: ADC as an imaging biomarker of tumor behavior and therapeutic response. Eur J Radiol. 2021. PMID: 33647779. doi:10.1016/j.ejrad.2021.109609

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。